3 QUESTIONS ON . . . The Impact of Historical Redlining on… : Oncology Times
An abstract is unavailable.
An abstract is unavailable.
A panel of experts on multiple myeloma review patient cases and discuss the treatment of patients with relapsed/refractory disease, highlighting sequencing strategies and clinical trials…
Luveltamab tazevibulin produced responses in patients with platinum-resistant ovarian cancer.
Oncogene – A TBX2-driven signaling switch from androgen receptor to glucocorticoid receptor confers therapeutic resistance in prostate cancer
h is composed of three commonly recorded intraoperative variables, predicts postoperative complications after various types of spine surgery. This has not; however, been studied in…
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, comments on the recent developments in the treatment of acute myeloid leukemia (AML), sharing…
With the Oncology Brothers, Uma Borate, MD, discusses how the combination of venetoclax with an IDH1 inhibitor and 7+3 chemotherapy leads to higher remission rates…
Tamoxifen reduced the risk of invasive ipsilateral breast recurrence in patients with good-risk ductal carcinoma in situ.
Our findings suggest that NF1 individuals may have a higher risk for developing melanomas and tend to have thicker melanomas and worse survival compared to…
Cancer touches all of us. Our mission – to contribute to the prevention and cure of cancer – depends on your support. There are many…
A breast cancer diagnosis is almost always followed by invasive biopsies, surgery, radiotherapy, chemotherapy and hormone treatments. But could all that be set to change?